Janney Montgomery Scott LLC Boosts Stock Position in ADMA Biologics Inc (NASDAQ:ADMA)

Janney Montgomery Scott LLC boosted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 7.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 70,991 shares of the biotechnology company’s stock after purchasing an additional 4,865 shares during the quarter. Janney Montgomery Scott LLC’s holdings in ADMA Biologics were worth $1,408,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in ADMA Biologics during the 4th quarter worth approximately $19,076,000. JPMorgan Chase & Co. increased its holdings in ADMA Biologics by 272.5% during the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company’s stock worth $13,159,000 after purchasing an additional 561,310 shares during the last quarter. Victory Capital Management Inc. increased its holdings in ADMA Biologics by 52.8% during the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company’s stock worth $1,886,000 after purchasing an additional 38,002 shares during the last quarter. Sei Investments Co. increased its holdings in shares of ADMA Biologics by 147.2% in the 4th quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company’s stock valued at $9,043,000 after acquiring an additional 314,013 shares during the last quarter. Finally, Swiss National Bank increased its holdings in shares of ADMA Biologics by 6.6% in the 4th quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company’s stock valued at $7,862,000 after acquiring an additional 28,500 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 1.3%

NASDAQ:ADMA opened at $18.16 on Friday. ADMA Biologics Inc has a 12-month low of $10.21 and a 12-month high of $25.67. The firm has a market capitalization of $4.34 billion, a P/E ratio of 21.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The business has a 50 day simple moving average of $20.63 and a 200 day simple moving average of $18.76.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same quarter in the prior year, the firm earned $0.08 EPS. The company’s revenue for the quarter was up 40.2% compared to the same quarter last year. Equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director now owns 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director now owns 87,330 shares of the company’s stock, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 in the last 90 days. 3.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ADMA shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. Finally, Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.